Why this matters.

PSA Alone Can Be Misleading

PSA testing measures a single marker that can be elevated for many non-cancer reasons—often creating anxiety, unnecessary follow-ups, or unclear results.

The PHI test improves accuracy by combining multiple prostate biomarkers into one score, helping identify cancer risk earlier and more reliably.

Shrinking the “gray zone”:
the difference between PSA alone and PHi.

Good. Thumbs up icon

PSA is a valuable screening marker, but it is not specific to prostate cancer.

PSA can be elevated due to benign prostate enlargement or inflammation, which may lead to additional testing and biopsy even when cancer is not present.

Better. Two thumbs up icon

PHI (Prostate Health Index) is a blood test designed to improve risk assessment beyond PSA alone.

PHI combines total PSA, free PSA, and p2PSA ([-2]proPSA) into a single score that more accurately estimates the likelihood of prostate cancer—particularly when PSA falls in the commonly encountered “gray zone” (often 4–10 ng/mL).

PSA vs PHI

1 in 8
men will develop prostate cancer
99%
5‑year survival when diagnosed at Stage 1
41%
5‑year survival when diagnosed at Stage 4

How PHI screening makes a difference:


Drop target icon

Improves risk stratification
compared with PSA alone

Drop user plus icon

Supports more informed biopsy decisions,
especially in the PSA gray zone

Drop down arrow icon

Reduces unnecessary biopsies
(reported reductions up to ~30% in appropriate patients)
FDA Approved

FDA-Approved for Prostate Cancer Risk Assessment


The PHI test is FDA approved and supported by clinical studies showing greater specificity than PSA alone.

Clipboard icon

PHi results should be interpreted by a clinician in the context of age, exam findings, family history, and other risk factors.


1 Disclaimer: This information is not a substitute for medical advice.